Andrew Payne
About Andrew Payne
Andrew Payne serves as the Head of Discovery Biology at Exscientia, a position he has held since 2019. He previously worked at UCB for 15 years in various leadership roles and has a PhD in antifungal discovery from the University of Bristol.
Current Role at Exscientia
Andrew Payne serves as the Head of Discovery Biology at Exscientia, a position he has held since 2019. In this role, he leads initiatives focused on biological discovery, contributing to the development of innovative therapeutic strategies. His work is based in Oxford, United Kingdom, where he oversees various projects aimed at advancing drug discovery processes.
Previous Experience at Exscientia
Prior to his current role, Andrew Payne worked at Exscientia as the Collaborations Pharmacology Director from 2018 to 2019. During this year, he was involved in pharmacological collaborations, enhancing the company's capabilities in drug development and research partnerships.
Career at UCB
Andrew Payne spent 15 years at UCB, where he held multiple positions, including Group Leader and Senior Group Leader of the Primary Pharmacology Group. His tenure at UCB lasted from 2003 to 2018, during which he contributed to various pharmacological research projects and team leadership efforts.
Education and Expertise
Andrew Payne earned his PhD from the University of Bristol, where he focused on antifungal discovery, target identification, and assay development. His academic background provides a strong foundation for his work in drug discovery and pharmacology, equipping him with specialized knowledge in these areas.